
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
Case: A 73-Year-Old Woman With Differentiated Thyroid Cancer
Initial Presentation
Clinical Work-up and Initial Treatment
Subsequent Treatment and Follow-up






